This project has the ability to extend digital clinical measures to larger audiences.
Adherence specialists AARDEX Group announced its partnership with other industry leaders on DiMe Digital Medicine Society’s new Extending the Verification, Analytical Validation, and Clinical Validation (V3+) Framework project.
Organizations are taking digital clinical measures and products to scale, meaning digital health technologies (DHTs) must meet the needs of larger audiences. DiMe’s existing V3 Framework is the go-to guide for evaluating whether sensor-based DHTs are fit for purpose from a technical, scientific, and clinical performance of the product perspective.
The goal of the new V3+ project is to build on this success by adding evidence-based components that ensure DHTs meet the needs of all users through the application of best practices in usability, human factors, and human-centered design.
Continue reading this story here.
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.